china tirzepatide Clears Eli Lilly's Weight Loss Drug Tirzepatide, Only For Diabetes China approves Eli Lilly's blockbuster
Description
Taste disturbances are generally temporary and tend to resolve as the body adjusts to the medication, typically within the first few weeks of treatment
That trial, called SURPASS-CVOT, will finish in mid-2025 and could really give us the details we need to see how effective tirzepatide is in reducing heart disease, he says
Diarrhea, vomiting, decreased appetite, constipation, and abdominal pain are all documented
Some choose to stay at 10 mg long-term rather than continuing to higher doses
